. Author manuscript; available in PMC: 2014 Sep 1.

Published in final edited form as: Psychopharmacology (Berl). 2013 Apr 6;229(1):83–94. doi: 10.1007/s00213-013-3088-7

Table 3.

Effects of yohimbine on IMT performance

Measure (n=22)	Baseline	Maximum Change (Δ)	Univariate Effect Size for Δ	Repeated measures
Measure (n=22)	Baseline	Maximum Change (Δ)	Univariate Effect Size for Δ	F (df)	P
Correct detections (%)	82.1 ± 13.6	−2.17 ± 8.27	0.262	1.47 (4,68)	0.23
Commission errors (%)	22.1 ± 14.4	2.64 ± 6.04	0.447	4.41 (4,76)	0.003
Random errors (%)	0.49 ± 0.99	0.61 ± 4.18	0.146	0.48 (4,80)	0.75
Commission Errors/Corr. Detections	0.276 ± 0.166	0.044 ± 0.103	0.427	2.64 (4,80)	0.044
Reaction time, CD (msec)	473 ± 83	−42 ± 39	−1.077	3.05 (4,80)	0.022
Reaction time, CE (msec)	477 ± 89	−33 ± 55	−0.600	3.53 (4,76)	0.011
Discriminability	0.873 ± 0.065	−0.023 ± 0.065	−0.354	0.78 (4,76)	0.54
Response Bias	−0.083 ± 0.555	−0.196 ± 0.422	−0.465	3.02 (4,76)	0.023

Means are given with standard deviations. Analyses for correct detections, commission errors, random errors, disciminability, and response bias used age and education as covariates; analyses of reaction times used age as covariate. Effect size (for Δ) is the effect size for the maximum difference between net change from baseline with administration of yohimbine versus placebo. Significant effects (p < 0.05) are shown in bold face.